Back to Stocks

MIRM

Mirum Pharmaceuticals, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Mirum Pharmaceuticals is demonstrating a powerful transition from a speculative biotech to a disciplined commercial entity.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative surrounding its pipeline, Mirum faces a precarious financial reality. The company's operational cash burn is accelerating, with a Q1 2026 operating loss of approximately $228.8 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every MIRM filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical inflection point, balancing aggressive portfolio expansion against significant operational headwinds. The massive non-cash charge from the Bluejay acquisition obscures the underlying operational performance, but the growth in product sales confirms that Mirum's commercial engine is functioning. However, the disparity between the 'accounting loss' and the 'cash burn' is where the real investment risk resides. Investors must weigh the high-probability revenue growth of Livmarli and the potential of the new pipeline assets against the looming threat of patent litigation and the necessity for future capital. The successful launch of zilurgisertib and the results of the brelovitug trials will likely determine if Mirum can achieve self-sufficiency or if it will remain dependent on the capital markets to survive its own growth trajectory.

Selected Quarter

Core Takeaway

Mirum is growing rapidly and acquiring new assets, but high operational burn and patent litigation create a volatile risk-reward profile.

Investor Lens

The trade-off is between the high-conviction pipeline catalysts and the risk of a liquidity crunch or patent loss.

Watch Next

PDUFA date for zilurgisertib on September 26, 2026, and brelovitug topline data in H2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.15Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 6

Reported a massive net loss of $790.2M, though primarily due to non-cash acquisition charges.

earnings miss
90%
bullishMay 6

Maintaining high gross margins of approximately 82% on growing product sales.

margin expansion
80%
bullishMay 6

Successfully completed a private placement resulting in $259.9M in net proceeds.

capital raise
70%
neutralMay 6

Facing consolidated patent litigation regarding Livmarli generic entry.

regulatory action
60%
bearishMay 6

Reported a massive net loss of $790.2M, though primarily due to non-cash acquisition charges.

earnings miss
90%
bullishMay 6

Maintaining high gross margins of approximately 82% on growing product sales.

margin expansion
80%
bullishMay 6

Successfully completed a private placement resulting in $259.9M in net proceeds.

capital raise
70%
neutralMay 6

Facing consolidated patent litigation regarding Livmarli generic entry.

regulatory action
60%
bearishMay 6

Reported a massive net loss of $790.2M, though primarily due to non-cash acquisition charges.

earnings miss
90%
bullishMay 6

Maintaining high gross margins of approximately 82% on growing product sales.

margin expansion
80%
bullishMay 6

Successfully completed a private placement resulting in $259.9M in net proceeds.

capital raise
70%
neutralMay 6

Facing consolidated patent litigation regarding Livmarli generic entry.

regulatory action
60%
bearishMay 6

Reported a massive net loss of $790.2M, though primarily due to non-cash acquisition charges.

earnings miss
90%
bullishMay 6

Maintaining high gross margins of approximately 82% on growing product sales.

margin expansion
80%
bullishMay 6

Successfully completed a private placement resulting in $259.9M in net proceeds.

capital raise
70%
neutralMay 6

Facing consolidated patent litigation regarding Livmarli generic entry.

regulatory action
60%
bearishMay 6

Reported a massive net loss of $790.2M, though primarily due to non-cash acquisition charges.

earnings miss
90%
bullishMay 6

Maintaining high gross margins of approximately 82% on growing product sales.

margin expansion
80%
bullishMay 6

Successfully completed a private placement resulting in $259.9M in net proceeds.

capital raise
70%
neutralMay 6

Facing consolidated patent litigation regarding Livmarli generic entry.

regulatory action
60%
bearishMay 6

Reported a massive net loss of $790.2M, though primarily due to non-cash acquisition charges.

earnings miss
90%
bullishMay 6

Maintaining high gross margins of approximately 82% on growing product sales.

margin expansion
80%
bullishMay 6

Successfully completed a private placement resulting in $259.9M in net proceeds.

capital raise
70%
neutralMay 6

Facing consolidated patent litigation regarding Livmarli generic entry.

regulatory action
60%
bearishMay 6

Reported a massive net loss of $790.2M, though primarily due to non-cash acquisition charges.

earnings miss
90%
bullishMay 6

Maintaining high gross margins of approximately 82% on growing product sales.

margin expansion
80%
bullishMay 6

Successfully completed a private placement resulting in $259.9M in net proceeds.

capital raise
70%
neutralMay 6

Facing consolidated patent litigation regarding Livmarli generic entry.

regulatory action
60%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical inflection point, balancing aggressive portfolio expansion against significant operational headwinds. The massive non-cash charge from the Bluejay acquisition obscures the underlying operational performance, but the growth in product sales confirms that Mirum's commercial engine is functioning. However, the disparity between the 'accounting loss' and the 'cash burn' is where the real investment risk resides. Investors must weigh the high-probability revenue growth of Livmarli and the potential of the new pipeline assets against the looming threat of patent litigation and the necessity for future capital. The successful launch of zilurgisertib and the results of the brelovitug trials will likely determine if Mirum can achieve self-sufficiency or if it will remain dependent on the capital markets to survive its own growth trajectory.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.